OncoMatch/Clinical Trials/NCT06104553
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
Is NCT06104553 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including SHR-A1912; R-Chemo and SHR-A1912; R-Chemo for b-cell non-hodgkin's lymphoma.
Treatment: SHR-A1912; R-Chemo · SHR-A1912; R-Chemo — This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic anti-tumor therapy — relapsed/refractory cohort: at least one (≥ 1) line of prior systemic therapy
Relapsed and/or refractory disease after at least one (≥ 1) line of prior systemic therapy (relapsed/refractory cohort)
Cannot have received: autologous stem cell transplant
Exception: allowed if >12 weeks before first study treatment
Received autologous stem cell transplantation within 12 weeks before the first study treatment
Cannot have received: allogeneic stem cell transplant
previously received allogeneic stem cell transplantation
Cannot have received: CAR-T cell therapy
Exception: allowed if >12 weeks before first study treatment
received Car-T cell therapy within 12 weeks before the first study treatment
Cannot have received: anti-tumour treatment
Exception: allowed if >2 weeks before first study treatment
Received anti-tumour treatment within 2 weeks before the first study treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify